Joseph A R Englert1, Jennifer A Davis1, Selim R Krim2. 1. Department of Cardiology, Ochsner Clinic Foundation, New Orleans, LA. 2. Department of Cardiology, Ochsner Clinic Foundation, New Orleans, LA ; The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA.
Abstract
BACKGROUND: Heart transplantation remains the definitive therapy for patients with advanced heart failure; however, owing to limited donor organ availability and long wait times, continuous-flow left ventricular assist devices (LVADs) have become standard therapy. METHODS: This review summarizes the history, progression, function, and basic management of LVADs. Additionally, we provide some clinical pearls and important caveats for managing this unique patient population. RESULTS: Currently, the most common LVADs being implanted in the United States are second- and third-generation devices, the HeartMate II (Thoratec Corp., St. Jude Medical) and the HeartWare HVAD (HeartWare International, Inc.). A newer third-generation pump, the HeartMate III (Thoratec Corp., St. Jude Medical), is designed to create an artificial pulse and is currently under investigation in the United States. CONCLUSION: LVAD use is promising, will continue to grow, and has become standard therapy for advanced heart failure as a bridge to recovery, as destination therapy, and as a bridge to transplantation.
BACKGROUND: Heart transplantation remains the definitive therapy for patients with advanced heart failure; however, owing to limited donor organ availability and long wait times, continuous-flow left ventricular assist devices (LVADs) have become standard therapy. METHODS: This review summarizes the history, progression, function, and basic management of LVADs. Additionally, we provide some clinical pearls and important caveats for managing this unique patient population. RESULTS: Currently, the most common LVADs being implanted in the United States are second- and third-generation devices, the HeartMate II (Thoratec Corp., St. Jude Medical) and the HeartWare HVAD (HeartWare International, Inc.). A newer third-generation pump, the HeartMate III (Thoratec Corp., St. Jude Medical), is designed to create an artificial pulse and is currently under investigation in the United States. CONCLUSION: LVAD use is promising, will continue to grow, and has become standard therapy for advanced heart failure as a bridge to recovery, as destination therapy, and as a bridge to transplantation.
Authors: Raymond F Stainback; Jerry D Estep; Deborah A Agler; Emma J Birks; Merri Bremer; Judy Hung; James N Kirkpatrick; Joseph G Rogers; Nishant R Shah Journal: J Am Soc Echocardiogr Date: 2015-08 Impact factor: 5.251
Authors: David Feldman; Salpy V Pamboukian; Jeffrey J Teuteberg; Emma Birks; Katherine Lietz; Stephanie A Moore; Jeffrey A Morgan; Francisco Arabia; Mary E Bauman; Hoger W Buchholz; Mario Deng; Marc L Dickstein; Aly El-Banayosy; Tonya Elliot; Daniel J Goldstein; Kathleen L Grady; Kylie Jones; Katarzyna Hryniewicz; Ranjit John; Annemarie Kaan; Shimon Kusne; Matthias Loebe; M Patricia Massicotte; Nader Moazami; Paul Mohacsi; Martha Mooney; Thomas Nelson; Francis Pagani; William Perry; Evgenij V Potapov; J Eduardo Rame; Stuart D Russell; Erik N Sorensen; Benjamin Sun; Martin Strueber; Abeel A Mangi; Michael G Petty; Joseph Rogers Journal: J Heart Lung Transplant Date: 2013-02 Impact factor: 10.247
Authors: Randall C Starling; Yoshifumi Naka; Andrew J Boyle; Gonzalo Gonzalez-Stawinski; Ranjit John; Ulrich Jorde; Stuart D Russell; John V Conte; Keith D Aaronson; Edwin C McGee; William G Cotts; David DeNofrio; Duc Thinh Pham; David J Farrar; Francis D Pagani Journal: J Am Coll Cardiol Date: 2011-05-10 Impact factor: 24.094
Authors: James K Kirklin; David C Naftel; Robert L Kormos; Lynne W Stevenson; Francis D Pagani; Marissa A Miller; Karen L Ulisney; J Timothy Baldwin; James B Young Journal: J Heart Lung Transplant Date: 2010-01 Impact factor: 10.247
Authors: Leslie W Miller; Francis D Pagani; Stuart D Russell; Ranjit John; Andrew J Boyle; Keith D Aaronson; John V Conte; Yoshifumi Naka; Donna Mancini; Reynolds M Delgado; Thomas E MacGillivray; David J Farrar; O H Frazier Journal: N Engl J Med Date: 2007-08-30 Impact factor: 91.245
Authors: Emma J Birks; Patrick D Tansley; James Hardy; Robert S George; Christopher T Bowles; Margaret Burke; Nicholas R Banner; Asghar Khaghani; Magdi H Yacoub Journal: N Engl J Med Date: 2006-11-02 Impact factor: 91.245
Authors: Lynne Warner Stevenson; Francis D Pagani; James B Young; Mariell Jessup; Leslie Miller; Robert L Kormos; David C Naftel; Karen Ulisney; Patrice Desvigne-Nickens; James K Kirklin Journal: J Heart Lung Transplant Date: 2009-06 Impact factor: 10.247
Authors: William L Holman; Walter E Pae; Jeffrey J Teutenberg; Michael A Acker; David C Naftel; Benjamin C Sun; Carmelo A Milano; James K Kirklin Journal: J Am Coll Surg Date: 2009-02-01 Impact factor: 6.113
Authors: Muhammad Shahreyar; Tamunoinemi Bob-Manuel; Rami N Khouzam; Mohammad W Bashir; Samian Sulaiman; Oluwaseun Akinseye; Arindam Sharma; April Carter; Samuel Latham; Sanjay Bhandari; Arshad Jahangir Journal: Ann Transl Med Date: 2018-01
Authors: Christoph Gross; Heinrich Schima; Thomas Schlöglhofer; Kamen Dimitrov; Martin Maw; Julia Riebandt; Dominik Wiedemann; Daniel Zimpfer; Francesco Moscato Journal: Artif Organs Date: 2020-03-01 Impact factor: 3.094